Issue 34, 2020

A cell membrane vehicle co-delivering sorafenib and doxorubicin remodel the tumor microenvironment and enhance immunotherapy by inducing immunogenic cell death in lung cancer cells

Abstract

Cancer immunotherapy is a promising approach for cancer therapy but is usually hindered by the inhibition of the tumor microenvironment (TME). Herein, we developed a cell membrane vehicle (CV) to co-deliver doxorubicin (Dox) and sorafenib (Sfn) as a drug delivery system (CV/D–S) to regulate the TME and sensitize the immunogenic cell death (ICD)-induced immune response against tumors. The CV/D–S showed high stability, acid-responsive drug release, high biocompatibility with tumor-specific cellular uptake, and target-ability that preferably resulted in the in vitro and in vivo anticancer performance. Most importantly, the Dox in the DDS can induce significant ICD while Sfn was able to remodel the TME, downregulate Treg, activate effector T cells and relieve programmed cell death protein 1 (PD-1) expression. As a result, the synergistic effect of Dox and Sfn achieved strong immune response in CV/D–S treated mice, which is believed to open a new window for the design and development of future platforms for the more effective immunotherapy of cancer.

Graphical abstract: A cell membrane vehicle co-delivering sorafenib and doxorubicin remodel the tumor microenvironment and enhance immunotherapy by inducing immunogenic cell death in lung cancer cells

Article information

Article type
Paper
Submitted
22 Apr 2020
Accepted
13 Jul 2020
First published
18 Jul 2020

J. Mater. Chem. B, 2020,8, 7755-7765

A cell membrane vehicle co-delivering sorafenib and doxorubicin remodel the tumor microenvironment and enhance immunotherapy by inducing immunogenic cell death in lung cancer cells

J. Wan, J. Wang, M. Zhou, Z. Rao and X. Ling, J. Mater. Chem. B, 2020, 8, 7755 DOI: 10.1039/D0TB01052A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements